Immuneering (NASDAQ:IMRX) Rating Lowered to Underweight at Morgan Stanley

Immuneering (NASDAQ:IMRX) was downgraded by stock analysts at Morgan Stanley from an “equal weight” rating to an “underweight” rating in a note issued to investors on Friday,Briefing.com Automated Import reports.

IMRX has been the topic of several other research reports. Chardan Capital reaffirmed a “buy” rating and issued a $13.00 price target on shares of Immuneering in a research note on Wednesday, November 20th. Needham & Company LLC reaffirmed a “buy” rating and issued a $15.00 target price on shares of Immuneering in a research report on Thursday, November 14th. One investment analyst has rated the stock with a sell rating, three have given a hold rating and four have issued a buy rating to the company’s stock. Based on data from MarketBeat.com, the company currently has an average rating of “Hold” and a consensus target price of $12.80.

Immuneering Stock Performance

IMRX stock opened at $1.97 on Friday. Immuneering has a one year low of $1.00 and a one year high of $8.41. The firm has a market cap of $61.17 million, a PE ratio of -1.00 and a beta of -0.33. The firm’s 50 day moving average price is $2.07 and its 200-day moving average price is $1.68.

Institutional Trading of Immuneering

Large investors have recently modified their holdings of the stock. Vontobel Holding Ltd. purchased a new position in Immuneering in the third quarter worth approximately $25,000. Corsair Capital Management L.P. purchased a new position in Immuneering in the third quarter valued at $25,000. Point72 Asia Singapore Pte. Ltd. acquired a new stake in Immuneering in the second quarter valued at $44,000. XTX Topco Ltd lifted its holdings in Immuneering by 37.3% during the 2nd quarter. XTX Topco Ltd now owns 34,159 shares of the company’s stock worth $44,000 after buying an additional 9,274 shares during the last quarter. Finally, Acadian Asset Management LLC purchased a new stake in Immuneering during the 2nd quarter worth about $67,000. Hedge funds and other institutional investors own 67.65% of the company’s stock.

Immuneering Company Profile

Immuneering Corporation, a clinical-stage oncology company, engages in the development of medicines for broad populations of cancer patients. Its lead product candidates include IMM-1-104, a dual-MEK inhibitor currently under Phase 1/2a clinical trial to treat patients with cancer, including pancreatic, melanoma, colorectal, and non-small cell lung cancer caused by mutations of RAS and/or RAF; and IMM-6-415 is in Investigational New Drug application to treat solid tumors.